FORTIS-C: A Phase 3, Randomized, Placebo-Controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Carboplatin; Paclitaxel; Talactoferrin alfa
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORTIS-C
- 04 Aug 2011 Planned End Date changed from 1 Mar 2013 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 19 May 2009 New source identified and integrated (Agennix media release).
- 18 Feb 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.